BIIB
Biogen Inc.
Drug Manufacturers - General · Healthcare · United States
249.65
close · 2026-10-29
value
86
cheaper than peers86
quality
68
stronger fundamentals68
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 9.9% | 95 |
| cash flow yield, 1 year ago | 8.1% | 90 |
| cash flow yield, latest year | 6.4% | 88 |
| earnings yield, 2 years ago | 3.8% | 88 |
| earnings yield, 1 year ago | 5.3% | 86 |
| earnings yield, latest year | 4.2% | 78 |
| cash flow yield, 3 years ago | 3.7% | 73 |
| cash flow yield, 2 years ago | 4.0% | 71 |
| price to book | 1.95× | 70 |
| forward P/E | 15.34× | 64 |
| EV to EBITDA | 13.22× | 60 |
| price to sales | 3.60× | 53 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 25.1% | 92 |
| return on equity | 4.6% | 75 |
| debt to equity | 44.3% | 43 |
| revenue growth | 3.4% | 33 |
4 of 4 measures available
Facts
| market cap | $37B |
| free cash flow | $1.27B |
| employees | 7,500 |
| first trade | 1991-09-17 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 8.79 | 11.18 | 7.97 | 20.87 |
| free cash flow | $1.97B | $2.52B | $1.24B | $1.14B |
| net income | $1.29B | $1.63B | $1.16B | $3.05B |
| revenue | $9.89B | $9.68B | $9.84B | $10.17B |
| unusual items | -$794.7M | -$277.0M | -$580.9M | $857.3M |